Ovarian Carcinoma: Current Diagnostic Principles

1. Ayhan, A., Kurman, R.J., Yemelyanova, A. et al.: Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am. J. Surg. Pathol., 2009, 33: 1220–1224.

2. Bowen, N.J., Walker, L.D., Matyunina, L.V. et al.: Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med. Genomics, 2009, 2: 71.

3. Bristow, R.E., Tomacruz, R.S., Armstrong, D.K., Trimble, E.L., Montz, F.J.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol., 2002, 20: 1248–1259.

4. Burks, R.T., Sherman, M.E., Kurman, R.J.: Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am. J. Surg. Pathol., 1996, 20: 1319–1330.

5. Cantrell, L.A., Van Le, L.: Carcinosarcoma of the ovary: a review. Obstet. Gynecol. Surv., 2009, 64: 673–680.

6. Cho, K.R.: Ovarian cancer update: lessons from morphology, molecules, and mice. Arch. Pathol. Lab. Med., 2009, 133: 1775–1781.

7. Cuatrecasas, M., Catasus, L., Palacios, J., Prat, J.: Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am. J. Surg. Pathol., 2009, 33: 556–567.

8. Dubé, V., Roy, M., Plante, M., Renaud, M.C., Tźtu, B.: Mucinous ovarian tumors of Mullerian-type: an analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas. Int J Gynecol. Pathol., 2005, 24: 138–146.

9. Euscher, E.D., Malpica, A., Deavers, M.T., Silva, E.G.: Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am. J. Surg. Pathol., 2005, 29: 1074–1078.

10. Folkins, A.K., Jarboe, E.A., Saleemuddin, A. et al.: A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol., 2008, 109: 168–173.

11. Hart, W.R.: Mucinous tumors of the ovary: a review. Int. J. Gynecol. Pathol., 2005, 24: 4-25.

12. Kikkawa, F., Kawai, M., Tamakoshi, K. et al.: Mucinous carcinoma of the ovary. Clinicopathologic analysis. Oncology, 1996, 53: 303–307.

13. Köbel, M., Kalloger, S.E., Carrick, J. et al.: A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am. J. Surg. Pathol., 2009, 33: 14–21.

14. Köbel, M., Kalloger, S.E., Santos, J.L., Huntsman, D.G., Gilks, C.B., Swenerton, K.D.: Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol. Oncol., 2010, 116: 50–56.

15. Kuo, K.T., Mao, T.L., Jones, S. et al.: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol., 2009, 174: 1597-1601.

16. Kurman, R.J., Shih, I.M.: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol., 2010, 34: 433–443.

17. Lee, K.R., Young, R.H.: The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am. J. Surg. Pathol., 2003, 27: 281–292.

18. Levanon, K., Crum, C., Drapkin, R.: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol., 2008, 26: 5284–5293.

19. Logani, S., Oliva, E., Amin, M.B., Folpe, A.L., Cohen, C., Young, R.H.: Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am. J. Surg. Pathol., 2003, 27:1434–1441.

20. Madore, J., Ren, F., Filali-Mouhim, A. et al.: Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J. Pathol., 2010, 220: 392–400.

21. Malpica, A., Deavers, M.T., Lu, K. et al.: Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol., 2004, 28: 496–504.

22. McAlpine, J.N., Wiegand, K.C., Vang, R. et al.: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 2009, 9: 433.

23. McCluggage, W.G., Young, R.H.: Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor. Am. J. Surg. Pathol., 2008, 32: 1373–1379.

24. Nonaka, D., Chiriboga, L., Soslow, R.A.: Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am. J. Surg. Pathol., 2008, 32: 1566–1571.

25. O’Neill, C.J., Deavers, M.T., Malpica, A., Foster, H., McCluggage, W.G.: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am. J. Surg. Pathol., 2005, 29: 1034–1041.

26. O’Neill, C.J., McBride, H.A., Connolly, L.E., Deavers, M.T., Malpica, A., McCluggage, W.G.: High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology, 2007, 50: 773–779.

27. Phillips, V., Kelly, P., McCluggage, W.G.: Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int. J. Gynecol. Pathol., 2009, 28: 179–186.

28. Provenza, C., Young, R.H., Prat, J.: Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am. J. Surg. Pathol., 2008, 32: 383–389.

29. Sarrió, D., Moreno-Bueno, G., Sánchez-Estévez, C. et al.: Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum. Pathol., 2006, 37: 1042–1049.

30. Schipf, A., Mayr, D., Kirchner, T., Diebold, J.: Molecular genetic aberrations of ovarian and uterine carcinosarcomas – a CGH and FISH study. Virchows Arch., 2008, 452: 259–268.

31. Shaw, P.A., McLaughlin, J.R., Zweemer, R.P. et al.: Histopathologic features of genetically determined ovarian cancer. Int. J. Gynecol. Pathol., 2002, 21: 407–411.

32. Shaw, P.A., Rouzbahman, M., Pizer, E.S., Pintilie, M., Begley, H.: Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod. Pathol., 2009, 22: 1133–1138.

33. Shih, I.M., Kurman, R.J.: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol., 2004, 164: 1511–1518.

34. Shimizu, Y., Kamoi, S., Amada, S., Akiyama, F., Silverberg, S.G.: Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer, 1998, 82: 893–901.

35. Singer, G., Oldt, R. 3rd, Cohen, Y. et al.: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst., 2003, 95: 484–486.

36. Tabrizi, A.D., Kalloger, S.E., Köbel, M. et al.: Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int. J. Gynecol. Pathol., 2010, 29: 99–107.

37. Tavassoli, F.A., Devilee, P (Eds.): WHO Classification of Tumours: Tumours of the Breast and Female Genital Organs. 2003, IARC Press, Lyon.

38. Vang, R., Gown, A.M., Barry, T.S., Wheeler, D.T., Ronnett, B.M.: Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod. Pathol., 2006, 19: 97–105.

39. Vang, R., Gown, A.M., Barry, T.S. et al.: Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am. J. Surg. Pathol., 2006, 30: 1130–1139.

40. Vang, R., Gown, A.M., Farinola, M. et al.: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am. J. Surg. Pathol., 2007, 31: 653–663.

41. Vang, R., Shih, I.M., Kurman, R.J.: Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol., 2009, 16: 267–282.

42. Wong, K.K., Lu, K.H., Malpica, A. et al.: Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int. J. Gynecol. Pathol., 2007, 26: 404–409.

43. Yamamoto, S., Tsuda, H., Aida, S., Shimazaki, H., Tamai, S., Matsubara, O.: Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum. Pathol., 2007, 38: 1074–1080.